Strategic Business Reporting

**SECTION A** **Background:** AeroGrid Group is a rapidly expanding multinational entity operating in the renewable energy sector. Its functional and presentation currency is the Dollar ($). On 1 January 20X4, AeroGrid acquired a 30% equity interest in BreezeTech, a wind-turbine manufacturer located in a foreign jurisdiction whose functional currency is the Krona (KR). This investment gave AeroGrid significant influence, and it was correctly accounted for as an associate. The cost of the 30% investment was $40 million. On 1 July 20X4, AeroGrid acquired a further 50% of the equity shares in BreezeTech for a cash consideration of $120 million, achieving control. **Additional Information at 1 July 20X4:** 1. The fair value of AeroGrid's previously held 30% interest in BreezeTech was determined to be $65 million. 2. The fair value of the identifiable net assets of BreezeTech was $180 million. 3. AeroGrid has chosen to measure the non-controlling interest (NCI) in BreezeTech at fair value. The fair value of the 20% NCI at 1 July 20X4 was $45 million. 4. BreezeTech's net assets included an unrecognised internally generated patent for blade aerodynamics. The fair value of this patent was reliably measured at $15 million and is included in the $180 million net asset valuation. **Year-End Translation (31 December 20X4):** BreezeTech's operations are highly autonomous. At the year-end, the exchange rates fluctuated significantly. AeroGrid's directors are unsure how to treat the goodwill arising on acquisition and the fair value adjustments when translating BreezeTech's financial statements into Dollars for consolidation purposes. **Required:** **(a)** Discuss the financial reporting principles under IFRS 3 *Business Combinations* for accounting for the step acquisition of BreezeTech on 1 July 20X4, including the treatment of the previously held equity interest. (10 marks) **(b)** Calculate the goodwill arising on the acquisition of BreezeTech on 1 July 20X4, and explain the recognition of the internally generated patent in the consolidated financial statements. (10 marks) **(c)** Advise the directors of AeroGrid on the application of IAS 21 *The Effects of Changes in Foreign Exchange Rates* regarding the translation of BreezeTech's results, goodwill, and fair value adjustments at the year-end 31 December 20X4. (10 marks)

**SECTION A** **Background:** NovaGene is a highly innovative biotechnology startup. The company is currently seeking a Series B funding round from venture capitalists. The funding is contingent upon NovaGene demonstrating a strong balance sheet and meeting specific asset-to-debt covenants. During the year ended 31 March 20X5, NovaGene incurred $8 million in costs related to early-stage clinical trials for a new gene therapy. The technical feasibility of the therapy is still highly uncertain, and regulatory approval is at least three years away. The CFO has instructed the financial accountant to capitalise $5 million of these costs as 'Development Expenditure' under IAS 38 *Intangible Assets*, arguing that the therapy has massive commercial potential. Furthermore, to improve liquidity, the CFO arranged a transaction involving NovaGene's main laboratory building. The building was 'sold' to a financial institution for $20 million (its fair value) and immediately leased back for 15 years. The lease terms dictate that NovaGene retains all risks and rewards of the building, and there is a mandatory repurchase clause at the end of the lease term. The CFO has instructed the accountant to derecognise the building and recognise the $20 million as revenue from a contract with a customer under IFRS 15. The financial accountant is a qualified ACCA member and feels uncomfortable with these instructions. **Required:** **(a)** Discuss the correct financial reporting treatment for the clinical trial costs (IAS 38) and the sale and leaseback transaction (IFRS 15 / IFRS 16). (12 marks) **(b)** Evaluate the ethical issues faced by the financial accountant and advise on the appropriate actions they should take in accordance with the ACCA Code of Ethics and Conduct. (8 marks)

**SECTION B** **Background:** Ceres AgriCorp is a large-scale commercial farming enterprise specialising in viticulture (wine production). The company owns extensive vineyards. During the current reporting period, Ceres AgriCorp has faced two significant accounting issues: **Issue 1: Biological Assets** Ceres owns grapevines that have an expected productive life of 40 years. At the reporting date, the vines are bearing a heavy crop of grapes that are two weeks away from harvest. The directors are confused about whether the grapevines and the unharvested grapes should be accounted for under IAS 16 *Property, Plant and Equipment* or IAS 41 *Agriculture*, and how changes in fair value should be recognised. **Issue 2: Climate Change and Impairment** Ceres operates a large grape-processing facility. Recently, the region has experienced severe, unprecedented droughts linked to climate change, which are expected to reduce crop yields by 20% over the next decade and increase water procurement costs significantly. The directors are preparing a value-in-use (VIU) calculation to test the processing facility for impairment under IAS 36 *Impairment of Assets*. They have currently excluded the increased water costs from the cash flow projections, arguing they are 'future restructuring costs'. **Stakeholder Perspective:** Institutional investors have expressed frustration with Ceres AgriCorp's financial statements, noting that the profit or loss figure is highly volatile and makes it difficult to assess the underlying cash-generating performance of the business. **Required:** **(a)** Advise the directors on the correct accounting treatment for the grapevines and the unharvested grapes under IFRS standards. (8 marks) **(b)** Discuss how the climate change risks should be incorporated into the impairment review of the processing facility under IAS 36, and evaluate the directors' decision to exclude the increased water costs. (9 marks) **(c)** Explain to the directors why institutional investors might find the fair value accounting of biological assets challenging when interpreting the financial statements, and how investors might adjust their analysis. (8 marks)

**SECTION B** **Background:** Quantum Logistics is a global shipping and freight forwarding company. The company is exposed to significant volatility in marine fuel prices. **Issue 1: Hedge Accounting** On 1 October 20X4, to protect against rising fuel costs for a highly probable forecast voyage in March 20X5, Quantum entered into a forward contract to purchase 10,000 metric tons of marine fuel at a fixed price. Quantum designated this forward contract as a cash flow hedge under IFRS 9 *Financial Instruments*. At the year-end of 31 December 20X4, the fair value of the forward contract had increased by $400,000 due to rising global fuel prices. The hedge is determined to be 100% effective. **Issue 2: Restructuring Provision** Due to advancements in automated port logistics, Quantum's board of directors decided on 15 December 20X4 to close three of its European manual sorting hubs. A detailed formal plan was drafted. On 20 December 20X4, the board sent a letter to all affected employees notifying them of the impending redundancies and hub closures. The estimated redundancy costs are $2.5 million, and the cost of retraining staff to use the new automated systems is estimated at $500,000. **Issue 3: Variable Consideration** Quantum frequently charges its clients 'demurrage' fees. These are penalty fees charged if a client takes too long to load or unload a shipping container. Demurrage is highly variable and depends on port congestion and client efficiency. Historically, Quantum only recognised demurrage revenue when the cash was received. **Required:** **(a)** Explain the criteria for applying hedge accounting under IFRS 9, and detail how the forward contract should be accounted for in Quantum's financial statements for the year ended 31 December 20X4. (9 marks) **(b)** Discuss whether Quantum should recognise a provision for the restructuring under IAS 37 *Provisions, Contingent Liabilities and Contingent Assets* at 31 December 20X4, and determine the amount to be recognised. (8 marks) **(c)** Advise Quantum on how to account for the demurrage fees under IFRS 15 *Revenue from Contracts with Customers*, specifically addressing the treatment of variable consideration. (8 marks)

SECTION A Aeloria Energy is a European multinational renewable energy corporation with a functional currency of the Euro (€). You are the group accountant preparing the consolidated financial statements for the year ended 31 December 20X5. **Exhibit 1: Step Acquisition of Borealis Wind** On 1 January 20X3, Aeloria Energy acquired a 60% controlling interest in Borealis Wind, a company operating offshore wind farms in Norway, for 450 million Norwegian Krone (NOK). The functional currency of Borealis Wind is NOK. At this date, the fair value of Borealis Wind's identifiable net assets was NOK 600 million. Aeloria Energy chose to measure the non-controlling interest (NCI) at fair value, which was NOK 280 million. On 1 July 20X5, Aeloria Energy acquired an additional 20% of the equity shares in Borealis Wind for NOK 180 million. The fair value of Borealis Wind's net assets at this date was NOK 800 million. The carrying amount of the NCI in the consolidated financial statements immediately before this transaction was NOK 320 million. Exchange rates are as follows: - 1 January 20X3: €1 = NOK 10.0 - 1 July 20X5: €1 = NOK 10.5 - 31 December 20X5: €1 = NOK 11.0 - Average rate for 20X5: €1 = NOK 10.8 **Exhibit 2: Solaria Tech Joint Arrangement** On 1 January 20X5, Aeloria Energy entered into an arrangement with a competitor to establish 'Solaria Tech', a separate legal entity designed to develop next-generation solar panels. Aeloria Energy and the competitor each hold 50% of the voting rights. The legal form of Solaria Tech separates the assets and liabilities of the entity from the parties. However, a binding contractual agreement stipulates that Aeloria Energy and the competitor must purchase 100% of the solar panels produced by Solaria Tech in equal shares. The price of the panels is set to cover the production costs and administrative expenses of Solaria Tech, meaning it will operate at a break-even level. **Requirements:** (a) With reference to Exhibit 1, explain and calculate how the step acquisition of the additional 20% interest in Borealis Wind should be accounted for in the consolidated financial statements of Aeloria Energy for the year ended 31 December 20X5. (10 marks) (b) With reference to Exhibit 1, discuss the principles of translating the financial statements of Borealis Wind from NOK to Euros (€), including the specific treatment of goodwill and the calculation of exchange differences arising on translation for the year ended 31 December 20X5. (10 marks) (c) With reference to Exhibit 2, advise Aeloria Energy on the classification and accounting treatment of its interest in Solaria Tech in accordance with IFRS 11 Joint Arrangements. (10 marks)

SECTION A AquaPura Utilities is a publicly listed water treatment and supply company. You are the Financial Controller, reporting directly to the Chief Financial Officer (CFO). The financial year end is 31 December 20X5. **Exhibit 1: The Chemical Spill** In November 20X5, a malfunction at one of AquaPura's older treatment plants resulted in a significant chemical spill into a local river. The environmental protection agency immediately launched an investigation. By 31 December 20X5, the agency had not yet issued a formal fine, but AquaPura's legal counsel advised that a penalty of approximately $5 million is highly probable. Furthermore, AquaPura has a published environmental policy stating it will clean up any contamination it causes. The estimated cost of the cleanup is $8 million. The CFO has instructed you not to recognize any provision for the fine or the cleanup in the 20X5 financial statements. The CFO argues that since no formal legal notice has been received, there is no present obligation. The CFO wants to disclose it merely as a contingent liability. **Exhibit 2: Government Grant** On 1 October 20X5, AquaPura received a $12 million government grant to assist in the construction of a new, state-of-the-art eco-friendly water filtration plant. The plant will take two years to build and has an estimated useful life of 20 years. The CFO has directed you to recognize the entire $12 million as 'other income' in the statement of profit or loss for the year ended 31 December 20X5, stating that the company needs the profit boost to meet debt covenant requirements. The CFO has privately told you that if you process these transactions as requested, you will receive a 'special performance bonus' of $50,000 after the audit is signed off. **Requirements:** (a) Discuss the correct accounting treatment for the chemical spill (fine and cleanup costs) and the government grant in the financial statements of AquaPura Utilities for the year ended 31 December 20X5. (12 marks) (b) Discuss the ethical implications of the CFO's requests and the bonus offer for you as a professional accountant, referencing the fundamental principles of the ACCA Code of Ethics and Conduct. Recommend the actions you should take. (8 marks)

SECTION B Verdant Yields is a rapidly growing Agri-Tech startup specializing in vertical farming. The company cultivates high-value medicinal herbs indoors using advanced hydroponics. The company is preparing its financial statements for the year ended 31 December 20X5 and is currently seeking Series B funding from venture capital (VC) investors. **Exhibit 1: Medicinal Herbs** Verdant Yields plants seeds for a rare medicinal herb that takes 6 months to mature. As of 31 December 20X5, a large batch of these herbs is 3 months old (halfway through the growth cycle). The historical cost incurred for this batch (seeds, labor, nutrients) is $120,000. The fair value of the mature herbs at harvest is estimated to be $400,000. The fair value of the half-mature herbs currently in the vertical farm is estimated at $220,000. Estimated costs to sell at harvest are $20,000. **Exhibit 2: Warehouse Lease** On 1 January 20X5, Verdant Yields entered into a 10-year lease for a specialized climate-controlled warehouse. The initial annual lease payment is $100,000, payable in arrears on 31 December each year. The lease payments are subject to an annual increase linked to the Consumer Price Index (CPI). On 1 January 20X5, the CPI was 100. The interest rate implicit in the lease is 5%. On 31 December 20X5, the CPI increased to 104, meaning the payment due on 31 December 20X6 will be $104,000. **Exhibit 3: Share-Based Payments** To retain top talent, Verdant Yields granted 10,000 share options to its lead botanist on 1 January 20X5. The options vest on 31 December 20X7 (a 3-year vesting period), provided the botanist remains employed and the company successfully patents a new hydroponic nutrient formula (a non-market performance condition). On 1 January 20X5, the fair value of each option was $15. On 31 December 20X5, the fair value of each option rose to $18. Management estimates there is an 80% probability that the patent will be successfully registered by the end of 20X7. **Requirements:** (a) Advise Verdant Yields on the recognition and measurement of the medicinal herbs as of 31 December 20X5, in accordance with IAS 41 Agriculture. (8 marks) (b) Explain how the warehouse lease should be initially measured on 1 January 20X5, and how the change in the CPI should be accounted for in the financial statements for the year ended 31 December 20X5, in accordance with IFRS 16 Leases. (8 marks) (c) Discuss the accounting treatment for the share-based payment to the lead botanist for the year ended 31 December 20X5 under IFRS 2 Share-based Payment. Furthermore, explain to the prospective VC investors how this accounting treatment impacts the reported EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization). (9 marks)

SECTION B MediStream AI is a digital healthcare company providing telemedicine services and AI-driven diagnostic tools. The company is preparing its financial statements for the year ended 31 December 20X5. **Exhibit 1: Subscription Bundles** On 1 July 20X5, MediStream AI launched a new 'HealthPlus' package. Customers pay a single upfront fee of $1,200 for a 2-year subscription to the telemedicine platform and receive a proprietary biometric tracking device. If sold separately, the 2-year subscription costs $1,000 and the device costs $500. The device is fully functional on its own, but its data syncs seamlessly with the telemedicine platform. By 31 December 20X5, MediStream AI had sold 1,000 HealthPlus packages. **Exhibit 2: AI Algorithm Development** During 20X5, MediStream AI spent $2.5 million developing a new AI algorithm to detect early signs of skin cancer from smartphone photos. - $500,000 was spent on initial research and feasibility studies. - $1.5 million was spent on coding and testing the algorithm after management demonstrated the technical feasibility, intention to complete, and ability to sell the software. - $500,000 was spent on training medical staff on how to use the new software. Management wants to capitalize the entire $2.5 million as an intangible asset. **Exhibit 3: Deferred Tax and Climate Regulation** MediStream AI has accumulated tax losses of $4 million. The local tax authority allows these losses to be carried forward indefinitely to offset future taxable profits. The corporate tax rate is 25%. Historically, the company has been loss-making. However, management has prepared a 5-year forecast showing significant taxable profits starting in 20X7, driven by the new AI algorithm. Recently, the government announced strict new data-center energy consumption regulations (a climate-related initiative) effective from 20X6. Compliance will significantly increase MediStream AI's server hosting costs. Management has not factored these increased costs into their 5-year profit forecast. **Requirements:** (a) In accordance with IFRS 15 Revenue from Contracts with Customers, determine the performance obligations in the HealthPlus package and calculate the revenue to be recognized for the year ended 31 December 20X5. (9 marks) (b) Evaluate management's proposal to capitalize the entire $2.5 million spent on the AI algorithm in accordance with IAS 38 Intangible Assets. (8 marks) (c) Discuss the criteria for recognizing a deferred tax asset in relation to the tax losses under IAS 12 Income Taxes. Evaluate how the new climate-related regulations should impact management's assessment of future taxable profits and the recognition of the deferred tax asset. (8 marks)